UCB May Be Stagnating Today, But Promises There Will Be Growth Tomorrow
This article was originally published in The Pink Sheet Daily
Executive Summary
Generics hit UCB's 2009 sales hard, but the mid-cap pharma is looking to new drugs Cimzia and Vimpat for a return to growth.